Laboratory of Pharmaceutical Pharmacology








Laboratory of Pharmaceutical Pharmacology (founded 2001) aims to discover novel drug targets, investigates the molecular mechanisms of pharmacological action of drugs, as well as tests biological activity of novel compounds. The applied research projects are implemented in close collaboration with pharmaceutical industry. The research directions include cardiovascular, CNS and molecular pharmacology. Research methods cover in vivo and in vitro tests, including cell culture, isolated organs and mitochondria, gene expression analysis.

Recent publications

  1. Liepinsh E., Makrecka-Kuka M., Kuka J., Vilskersts R., Makarova E., Cirule H., Loza E., Lola D., Grinberga S., Pugovics O., Kalvinsh I., Dambrova M. Inhibition of L-carnitine biosynthesis and transport by methyl-γ-butyrobetaine decreases fatty acid oxidation and protects against myocardial infarction. Br. J. Pharmacol., 2015, 172(5):1319-1332.
  2. Liepinsh E., Makrecka M., Kuka J., Cirule H., Makarova E., Sevostjanovs E., Grinberga S., Vilskersts R., Lola D., Loza E., Stonans I., Pugovics O., Dambrova M. Selective inhibition of OCTN2 is more effective than inhibition of Gamma-butyrobetaine dioxygenase to decrease the availability of L-carnitine and to reduce myocardial infarct size. Pharmacological Research, 2014; 85:33-38.
  3. Zvejniece L., Vavers E., Svalbe B., Vilskersts R., Domracheva I., Vorona M., Veinberg G., Misane I., Stonans I., Kalvinsh I., Dambrova M. The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors. Br. J. Pharmacol. 2014, 171(3): 761-771.


  1. Dambrova M., Cirule H., Kalvins I., Liepins E., Makarova E., Stonans I., Misane I. Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes. WO2015044828 (A1) – 2015-04-02.
  2. Kalvins I., Dambrova M., Liepinsh E., Makarova E., Pugovics O., Grinberga S., Sevostjanovs E. Pharmaceutical composition for reducing the trimethylamine n-oxide level. WO2014/064630 (A1), 2014-05-01.
  3. Kalvins I., Vilskersts R., Pugovics O., Dambrova M., Stonans I., Kuka J., Liepins E., Loza E. Andrianovs V., Grinberga S., Gustina D., Lola D., Makrecka M. Use of 4-[ethyl-(dimethyl)ammonio]butanoate or pharmaceuticaly acceptable salt in the treatment of atherosclerosis. WO2014096133 (A1), 2014-06-26.